Samsung BioLogics, one of the global biologics development and manufacturing companies, announced that it received ISO 22301 certificate, the international standard Business Continuity Management System (BCMS), as the first Korean pharmaceutical company from BSI (British Standards Institution), a global certification association.
ISO 22301 certificate is a comprehensive standard published by the International Organization for Standardization (ISO) that represents the highest level of commitment to business continuity and disaster preparedness.
In the case of biopharmaceuticals, the production and supply of biologics is directly linked to the life of patients suffering from serious disease including cancer, so it is crucial to stably produce and recover from the crisis.
Accordingly, global pharmaceutical companies consider crisis systems critical and request a high level of crisis response system from their partners. Samsung BioLogics has launched internal task force composed of 16 teams and 22 people and has discovered a total of 573 projected risks for about two years, reflecting global customer’ needs.
Ultimately, Samsung BioLogics has established an emergency response scenario by anticipating the internal and external crisis that may happen in order to obtain ISO certification. Furthermore it has also proved that Samsung is able to maintain the continuity of management in a short period of time in case of unexpected emergency such as incident and disaster, by pre-setting and preparing the resources and time required to overcome the crisis.